Literature DB >> 5640822

The relationship between the components of cowpea mosaic virus. I. Two ribonucleoprotein particles necessary for the infectivity of CPMV.

A van Kammen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5640822     DOI： 10.1016/0042-6822(68)90241-9

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


× No keyword cloud information.
  7 in total

1.  Expression of bottom component RNA of cowpea mosaic virus in cowpea protoplasts.

Authors:  G Rezelman; R Goldbach; A Van Kammen
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

2.  Sequence homology adjacent to the 3' terminal poly(A) of cowpea mosaic virus RNAs.

Authors:  J W Davies; J Stanley; A Van Kammen
Journal:  Nucleic Acids Res       Date:  1979-09-25       Impact factor: 16.971

3.  Antibodies Against the Genome-Linked Protein VPg of Cowpea Mosaic Virus Recognize a 60,000-Dalton Precursor Polypeptide.

Authors:  P Zabel; M Moerman; F van Straaten; R Goldbach; A van Kammen
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

4.  Functions of the two particles of tobacco rattle virus.

Authors:  H L Sänger
Journal:  J Virol       Date:  1969-03       Impact factor: 5.103

5.  A protein linked to the 5' termini of both RNA components of the cowpea mosaic virus genome.

Authors:  J Stanley; P Rottier; J W Davies; P Zabel; A Van Kammen
Journal:  Nucleic Acids Res       Date:  1978-12       Impact factor: 16.971

6.  Estimation of the effective number of founders that initiate an infection after aphid transmission of a multipartite plant virus.

Authors:  Mónica Betancourt; Alberto Fereres; Aurora Fraile; Fernando García-Arenal
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  Chemical addressability of ultraviolet-inactivated viral nanoparticles (VNPs).

Authors:  Chris Rae; Kristopher J Koudelka; Giuseppe Destito; Mayra N Estrada; Maria J Gonzalez; Marianne Manchester
Journal:  PLoS One       Date:  2008-10-02       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.